Veldman Abigail, Kiewiet Mensiena B G, Heiner-Fokkema Margaretha Rebecca, Nelen Marcel R, Sinke Richard J, Sikkema-Raddatz Birgit, Voorhoeve Els, Westra Dineke, Dollé Martijn E T, Schielen Peter C J I, van Spronsen Francjan J
Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Department of Genetics, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Int J Neonatal Screen. 2022 Feb 24;8(1):17. doi: 10.3390/ijns8010017.
Newborn screening (NBS) aims to identify neonates with severe conditions for whom immediate treatment is required. Currently, a biochemistry-first approach is used to identify these disorders, which are predominantly inherited meta1bolic disorders (IMD). Next-generation sequencing (NGS) is expected to have some advantages over the current approach, for example the ability to detect IMDs that meet all screening criteria but lack an identifiable biochemical footprint. We have now designed a technical study to explore the use of NGS techniques as a first-tier approach in NBS. Here, we describe the aim and set-up of the NGS-first for the NBS (NGSf4NBS) project, which will proceed in three steps. In Step 1, we will identify IMDs eligible for NGS-first testing, based on treatability. In Step 2, we will investigate the feasibility, limitations and comparability of different technical NGS approaches and analysis workflows for NBS, eventually aiming to develop a rapid NGS-based workflow. Finally, in Step 3, we will prepare for the incorporation of this workflow into the existing Dutch NBS program and propose a protocol for referral of a child after a positive NGS test result. The results of this study will be the basis for an additional analytical route within NBS that will be further studied for its applicability within the NBS program, e.g., regarding the ethical, legal, financial and social implications.
新生儿筛查(NBS)旨在识别患有严重疾病且需要立即治疗的新生儿。目前,采用先进行生物化学检测的方法来识别这些疾病,这些疾病主要是遗传性代谢疾病(IMD)。预计下一代测序(NGS)相对于当前方法具有一些优势,例如能够检测出符合所有筛查标准但缺乏可识别生化特征的IMD。我们现在设计了一项技术研究,以探索将NGS技术用作NBS的一线方法。在此,我们描述了NBS的NGS优先(NGSf4NBS)项目的目标和设置,该项目将分三步进行。在第一步中,我们将根据可治疗性确定适合进行NGS优先检测的IMD。在第二步中,我们将研究用于NBS的不同技术NGS方法和分析工作流程的可行性、局限性和可比性,最终目标是开发一种基于NGS的快速工作流程。最后,在第三步中,我们将准备把这个工作流程纳入现有的荷兰NBS计划,并提出一个在NGS检测结果呈阳性后转诊儿童的方案。这项研究的结果将成为NBS内另一条分析途径的基础,该途径将进一步研究其在NBS计划中的适用性,例如在伦理、法律、财务和社会影响方面。